Search
Displaying results 2111 - 2120 of 3180 in total
Cinchonidine
go.drugbank.com/drugs/DB16831ExperimentalCategories: Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 Enzyme InhibitorsTyrosol
go.drugbank.com/drugs/DB16855ExperimentalSynonyms: p-TyrosolCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2A6 SubstratesNorclobazam
go.drugbank.com/drugs/DB17092InvestigationalSynonyms: N-desmethylclobazamCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 SubstratesRedaporfin
go.drugbank.com/drugs/DB17219InvestigationalSynonyms: 3,3',3'',3'''-(7,8,17,18-tetrahydroporphyrin-5,10,15,20-tetrayl)tetrakis(2,4-difluoro-n-methylbenzenesulfonamide), Benzenesulfonamide, 3,3',3'',3'''-(7,8,17,18-tetrahydro-21h,23h-porphine-5,10,15,20-tetrayl)tetrakis(2,4-difluoro-n-methyl-Categories: P-glycoprotein substratesGI-101
go.drugbank.com/drugs/DB17243InvestigationalGI-101 is a bi-specific fragment crystallizable region (Fc) fusion protein containing a cluster of differentiation 80 ectodomain as an N-terminal moiety and interleukin-2 variant as a C-terminal moiety
P-BCMA-101
go.drugbank.com/drugs/DB17371InvestigationalP-BCMA-101 is an autologous CAR-T therapy developed using Poseida’s piggyBac platform technology.
EGT-201
go.drugbank.com/drugs/DB17648ExperimentalEGT-201 is an adeno-associated viral vector serotype 9 (AAV9) vector-based gene therapy consisting of the alpha-N-acetyglucosaminidase (NAGLU) transgene.
Linafexor
go.drugbank.com/drugs/DB18031InvestigationalCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesGunagratinib
go.drugbank.com/drugs/DB18191ExperimentalCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates